abiraterone has been researched along with glucose, (beta-d)-isomer in 1 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (glucose, (beta-d)-isomer) | Trials (glucose, (beta-d)-isomer) | Recent Studies (post-2010) (glucose, (beta-d)-isomer) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 21,956 | 883 | 10,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CY; Chen, WT; Chiou, YS; Chou, FP; Hsu, WC; Huang, SC; Lyu, JW; Tsai, CT; Wu, TK | 1 |
1 other study(ies) available for abiraterone and glucose, (beta-d)-isomer
| Article | Year |
|---|---|
Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities.
Topics: Androstenes; Antineoplastic Agents; Bacteria; Catalytic Domain; Cell Line, Tumor; Cytochrome P-450 Enzyme Inhibitors; Glucosides; Glycosylation; HEK293 Cells; Humans; Molecular Docking Simulation; Pregnenolone; Protein Binding | 2020 |